Vol. 18/No. 03 | OncologyLive

Rolling Out Technology

February 18, 2017

It is always a balancing act to describe the introduction of new technology in the medical field. We seek to juggle enthusiasm for the potential of an exciting new platform with the complexities of the long road ahead that adopting new technology usually bring.

Complex Scenarios in Advanced Melanoma: Examining Three Patient Cases

February 08, 2017

Despite significant developments on the advanced melanoma treatment front, “many clinical scenarios remain where there is no clear-cut course of action," said Robert H.I. Andtbacka, MD, CM, during a recent OncLive Peer Exchange®.

Nab-Paclitaxel Paired With Anti-PD-L1 Immunotherapies in TNBC Studies

February 08, 2017

Combination regimens that pair nab-paclitaxel with PD-L1 checkpoint blockade immunotherapy agents are emerging as a robust area of investigation in triple-negative breast cancer, bolstered by clinical trial results that establish the chemotherapeutic agent as an effective partner for other therapies.

Liquid Biopsies Making Impact in Lung Cancer, Other Tumor Types

February 05, 2017

The noninvasive testing that has long been the goal of solid tumor analysis is making its presence felt in lung cancer, and other malignancies likely will not be far behind, experts say. Although many potential uses for liquid biopsies are envisioned, much work remains to be done to establish the clinical utility of these tests.

Enhanced Recovery Program Improves Outcomes After Colorectal Cancer Surgery

February 03, 2017

The adoption of enhanced recovery after surgery protocols can improve not only the outcomes of patients after a procedure but can also reduce hospital costs, as has been seen in an ERAS program in colorectal cancer at the University of Virginia Health System.

Practicing Oncology in the Gray Zone

February 01, 2017

"Uncertainty" is a routine dilemma when discussing a prognosis with a patient with cancer and his or her family. The prognosis is, at best, a statistical probability—assuming the available objective data are somewhat representative of the individual patient.